{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T01:32:27Z","timestamp":1778981547537,"version":"3.51.4"},"reference-count":26,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Funds for Creative Research Groups of China","award":["2009ZX09301-008-P-05"],"award-info":[{"award-number":["2009ZX09301-008-P-05"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Peptides"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1016\/j.peptides.2011.05.026","type":"journal-article","created":{"date-parts":[[2011,6,13]],"date-time":"2011-06-13T04:09:12Z","timestamp":1307938152000},"page":"1408-1414","source":"Crossref","is-referenced-by-count":5,"title":["A novel GLP-1 analog exhibits potent utility in the treatment of type 2 diabetes with an extended half-life and efficient glucose clearance in vivo"],"prefix":"10.1016","volume":"32","author":[{"given":"Ying","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiren","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lida","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianning","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.peptides.2011.05.026_bib0005","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/(SICI)1521-1878(199808)20:8<642::AID-BIES7>3.0.CO;2-K","article-title":"Glucagon-like peptide-1 (GLP-1): a gut hormone of potential interest in the treatment of diabetes","volume":"20","author":"Ahren","year":"1998","journal-title":"Bioessays"},{"key":"10.1016\/j.peptides.2011.05.026_bib0010","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1517\/14656566.7.8.1055","article-title":"Exenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus","volume":"7","author":"Briones","year":"2006","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.peptides.2011.05.026_bib0015","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jconrel.2010.01.024","article-title":"The fatty acid conjugated exendin-4 analogs for type 2 antidiabetic therapeutics","volume":"144","author":"Chae","year":"2010","journal-title":"J Control Release"},{"key":"10.1016\/j.peptides.2011.05.026_bib0020","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.jconrel.2009.10.025","article-title":"Biochemical, pharmaceutical and therapeutic properties of long-acting lithocholic acid derivatized exendin-4 analogs","volume":"142","author":"Chae","year":"2010","journal-title":"J Control Release"},{"issue":"Suppl. 5","key":"10.1016\/j.peptides.2011.05.026_bib0025","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.3949\/ccjm.76.s5.05","article-title":"Advances in therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors","volume":"76","author":"Davidson","year":"2009","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.peptides.2011.05.026_bib0030","doi-asserted-by":"crossref","first-page":"E873","DOI":"10.1152\/ajpendo.00452.2001","article-title":"GLP-1-(9-36) amide reduces blood glucose in anesthetized pigs by a mechanism that does not involve insulin secretion","volume":"282","author":"Deacon","year":"2002","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.peptides.2011.05.026_bib0035","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/nrd3148","article-title":"Liraglutide","volume":"9","author":"Drucker","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.peptides.2011.05.026_bib0040","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1271\/bbb.80742","article-title":"Development, characterization, and evaluation of a fusion protein of a novel glucagon-like peptide-1 (GLP-1) analog and human serum albumin in Pichia pastoris","volume":"73","author":"Gao","year":"2009","journal-title":"Biosci Biotechnol Biochem"},{"key":"10.1016\/j.peptides.2011.05.026_bib0045","first-page":"459","article-title":"Exenatide Amylin\/Eli Lilly","volume":"4","author":"Giannoukakis","year":"2003","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1016\/j.peptides.2011.05.026_bib0050","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jconrel.2008.09.091","article-title":"A new orally available glucagon-like peptide-1 receptor agonist, biotinylated exendin-4, displays improved hypoglycemic effects in db\/db mice","volume":"133","author":"Jin","year":"2009","journal-title":"J Control Release"},{"key":"10.1016\/j.peptides.2011.05.026_bib0055","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1210\/endo.136.8.7628397","article-title":"Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV","volume":"136","author":"Kieffer","year":"1995","journal-title":"Endocrinology"},{"key":"10.1016\/j.peptides.2011.05.026_bib0135","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/j.peptides.2011.04.001","article-title":"GLP-1 analogs containing disulfide bond exhibited prolonged half-life in vivo than GLP-1","author":"Li","year":"2011","journal-title":"Peptides"},{"key":"10.1016\/j.peptides.2011.05.026_bib0065","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1042\/BST0350713","article-title":"Peptide binding at the GLP-1 receptor","volume":"35","author":"Mann","year":"2007","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.peptides.2011.05.026_bib0070","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1055\/s-0029-1211750","article-title":"Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for type 2-diabetes","volume":"105","author":"Nauck","year":"1997","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"10.1016\/j.peptides.2011.05.026_bib0075","doi-asserted-by":"crossref","first-page":"13188","DOI":"10.1021\/bi010902s","article-title":"Exendin-4 and glucagon-like-peptide-1: NMR structural comparisons in the solution and micelle-associated states","volume":"40","author":"Neidigh","year":"2001","journal-title":"Biochemistry"},{"key":"10.1016\/j.peptides.2011.05.026_bib0080","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/BF03365101","article-title":"Glucagon-like peptide 1 (GLP-1)","volume":"149","author":"Parhofer","year":"2007","journal-title":"MMW Fortschr Med"},{"key":"10.1016\/j.peptides.2011.05.026_bib0085","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.metabol.2003.11.011","article-title":"Insulin secretion and incretin hormones after oral glucose in non-obese subjects with impaired glucose tolerance","volume":"53","author":"Rask","year":"2004","journal-title":"Metabolism"},{"key":"10.1016\/j.peptides.2011.05.026_bib0090","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1139\/y90-239","article-title":"Renal catabolism of human glucagon-like peptides 1 and 2","volume":"68","author":"Ruiz-Grande","year":"1990","journal-title":"Can J Physiol Pharmacol"},{"key":"10.1016\/j.peptides.2011.05.026_bib0095","first-page":"217","article-title":"Glucagon-like peptide-1 (GLP-1), new target for the treatment of type 2 diabetes","volume":"62","author":"Scheen","year":"2007","journal-title":"Rev Med Liege"},{"key":"10.1016\/j.peptides.2011.05.026_bib0100","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1179\/acb.2008.083","article-title":"New therapeutic approaches in type 2 diabetes","volume":"63","author":"Scheen","year":"2008","journal-title":"Acta Clin Belg"},{"key":"10.1016\/j.peptides.2011.05.026_bib0105","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/dmrr.329","article-title":"Glucose-stimulated signaling pathways in biphasic insulin secretion","volume":"18","author":"Straub","year":"2002","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.peptides.2011.05.026_bib0110","doi-asserted-by":"crossref","first-page":"611","DOI":"10.2337\/diabetes.49.4.611","article-title":"Effect of glucagon-like peptide 1(7-36) amide on glucose effectiveness and insulin action in people with type 2 diabetes","volume":"49","author":"Vella","year":"2000","journal-title":"Diabetes"},{"issue":"Suppl. 3","key":"10.1016\/j.peptides.2011.05.026_bib0115","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1463-1326.2009.01073.x","article-title":"The effects of glucagon-like peptide-1 on the beta cell","volume":"11","author":"Vilsboll","year":"2009","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.peptides.2011.05.026_bib0120","doi-asserted-by":"crossref","first-page":"e12734","DOI":"10.1371\/journal.pone.0012734","article-title":"Novel GLP-1 fusion chimera as potent long acting GLP-1 receptor agonist","volume":"5","author":"Wang","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.peptides.2011.05.026_bib0125","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/0006-291X(90)92041-W","article-title":"Suppression of synthesis and release of glucagon by glucagon-like peptide-1 (7-36 amide) without affect on mRNA level in isolated rat islets","volume":"167","author":"Yamato","year":"1990","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.peptides.2011.05.026_bib0130","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.peptides.2011.02.009","article-title":"Application of novel peptide (Pp1) improving the half-life of exendin-4 in vivo","author":"Zheng","year":"2011","journal-title":"Peptides"}],"container-title":["Peptides"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196978111002221?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196978111002221?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,11]],"date-time":"2019-06-11T17:37:43Z","timestamp":1560274663000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0196978111002221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":26,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["S0196978111002221"],"URL":"https:\/\/doi.org\/10.1016\/j.peptides.2011.05.026","relation":{},"ISSN":["0196-9781"],"issn-type":[{"value":"0196-9781","type":"print"}],"subject":[],"published":{"date-parts":[[2011,7]]}}}